Skip to main content
Fig. 2 | BMC Ophthalmology

Fig. 2

From: Risk factors for repeated dexamethasone intravitreal implant therapy for macular edema due to treatment-naïve branch retinal vein occlusion

Fig. 2

a Kaplan–Meier analysis stratified showed that the median time to the second Ozurdex treatment in the group older than 60 years was 3.96 months, whereas the median time to second treatment in the group younger than 60 years was greater than 50 months (p = 0.007). b The median time to the second Ozurdex treatment in the initial CRT > 375 μm group was 4.06 months, whereas the median time to the second treatment in the initial CRT < 375 μm group was greater than 50 months (p = 0.022). c The median time to the second Ozurdex treatment in the diabetes group was 3.93 months, whereas the median time to the second treatment in the patients without diabetes was greater than 50 months (p = 0.003). More than 60% of the patients without diabetes only needed a single injection during the follow-up period, which was a statistically significant difference from the patients with diabetes (p = 0.003)

Back to article page